Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT.
Patients treated with definitive chemoradiation for oropharyngeal squamous cell carcinoma (OPC) experience excellent outcomes but treatment toxicities remain significant. The adoption of intensity modulated radiation therapy (IMRT) reduced morbidity by allowing targeting of at risk areas while sparing uninvolved regions. We explored whether level V lymphatics (LVN) can be omitted from elective volumes in OPC.



This analysis included 408 patients treated for stage III/IV OPC with IMRT at our institution. For 295 (72.3%) patients, bilateral LVN were covered, while LVN were omitted in 113 (27.7%). Nodal staging was N2a or greater in 324 patients (79.4%). All but one received concurrent chemotherapy. Actuarial regional recurrence was calculated using the KM method with the event of interest defined as any regional recurrence; all others were censored. Univariate and multivariate analyses were performed on variables significantly associated with both the inclusion of elective LVN and regional recurrence.



After a median follow-up of 63.6months (range, 1.3-125months), there were no level V failures in either group. The 2-year cumulative rate of regional failure (RF) was 4.5% (95% CI=2.9-6.6) in the overall cohort, 2.2% (95% CI=0.1-5.9) in the LVN untreated group, and 5.4% (95% CI=3.4-8.1) in the LVN treated group. After adjusting for Stage and tobacco status, there was no significant difference between the two groups in RF (HR=1.75 95% CI=(0.61-5.07), p=0.30).



LVN can be safely omitted from the clinical target volume in locally advanced OPC without gross LVN involvement.
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Stanley
S
Gutiontov
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Jonathan
J
Leeman
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Benjamin
B
Lok
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Paul
P
Romesser
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Nadeem
N
Riaz
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
C Jillian
CJ
Tsai
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States.
Nancy
N
Lee
Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1250 First Avenue, Schwartz Building Mezzanine, New York, NY 10065, United States. Electronic address: mcbrides@mskcc.org.
Sean
S
McBride
D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated
Clinical target volume; HPV; IMRT; Level V; Oropharyngeal cancer; Radiation therapy; Volume de-escalation